Overview

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.

Phase:

PHASE4

Details

Lead Sponsor:

Alexion Pharmaceuticals, Inc.

Treatments:

Prednisolone
Prednisone
ravulizumab